Midostaurin exhibited a potent anti-tumor effect on rituximab-resistant Burkitt’s lymphoma (BL) cells by reducing the phosphorylation of PKC and promoting proapoptotic activity. Here, PRRT2 is linked to Burkitt lymphoma.